The extensive report on 'The Law & Economics of Compulsory Licensing (CL) for Very Expensive Medicines' stresses that a modernized, well-governed system for more effective CLs can remain an essential tool. But it should still be used with care in extraordinary circumstances and on a case by case basis. Also highlighted is the need for more transparency and that other mechanisms must be considered and optimized too.
Prof. Timo Minssen (X-officio’s Senior Advisor) who co-authored the report said: “The report is written in English and was drafted in response to a Belgian legislative proposal. Yet, in light of recent developments and the challenges that we are facing, it is definitely also relevant beyond the Belgian context. In particular also in the context of the current interest of the European Commission in CLs”.
The full report is available here